CSPG4 and melanoma: Previous studies showed the inhibition of CSPG4+ melanoma cells in vitro and in vivo with this agent and reported that antitumoural activity was enhanced in the presence of the sigma receptor (σR) rimcazole, also known to have selective antitumoural activity (46,47).